Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Espinet

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
JCI Insight|August 22, 2022
Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancerNiklas Krebs, Lukas Klein, Florian Wegwitz, et al.
Nature Genetics|February 24, 2015
Stromal gene expression defines poor-prognosis subtypes in colorectal cancerAlexandre Calon, Enza Lonardo, Antonio Berenguer-Llergo, et al.
Cell Reports|April 15, 2026
Regulatory elements in the Sox9 locus license the initiation of pancreatic ductal adenocarcinomaMarta Ballester, Anita Kurilla, Yifan Dai, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2018
Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumorsMagdolna Djurec, Osvaldo Graña, Albert Lee, et al.
Nature Cancer|February 5, 2022
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancerMengyu Tu, Lukas Klein, Elisa Espinet, et al.
Nature Communications|January 6, 2025
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancerLukas Klein, Mengyu Tu, Niklas Krebs, et al.
Science Translational Medicine|September 13, 2021
Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasisMahak Singhal, Nicolas Gengenbacher, Ashik Ahmed Abdul Pari, et al.
Cell Reports|May 31, 2023
Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancerMassimo Saini, Laura Schmidleitner, Helena Domínguez Moreno, et al.
Nature Medicine|February 9, 2016
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaElisa M Noll, Christian Eisen, Albrecht Stenzinger, et al.
EMBO Molecular Medicine|February 23, 2026
Epigenetic dysregulation of IRF9 drives excessive interferon signaling in COPDMaria Llamazares-Prada, Uwe Schwartz, Darius F Pease, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
JCI Insight|August 22, 2022
Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancerNiklas Krebs, Lukas Klein, Florian Wegwitz, et al.
Nature Genetics|February 24, 2015
Stromal gene expression defines poor-prognosis subtypes in colorectal cancerAlexandre Calon, Enza Lonardo, Antonio Berenguer-Llergo, et al.
Cell Reports|April 15, 2026
Regulatory elements in the Sox9 locus license the initiation of pancreatic ductal adenocarcinomaMarta Ballester, Anita Kurilla, Yifan Dai, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2018
Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumorsMagdolna Djurec, Osvaldo Graña, Albert Lee, et al.
Nature Cancer|February 5, 2022
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancerMengyu Tu, Lukas Klein, Elisa Espinet, et al.
Nature Communications|January 6, 2025
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancerLukas Klein, Mengyu Tu, Niklas Krebs, et al.
Science Translational Medicine|September 13, 2021
Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasisMahak Singhal, Nicolas Gengenbacher, Ashik Ahmed Abdul Pari, et al.
Cell Reports|May 31, 2023
Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancerMassimo Saini, Laura Schmidleitner, Helena Domínguez Moreno, et al.
Nature Medicine|February 9, 2016
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaElisa M Noll, Christian Eisen, Albrecht Stenzinger, et al.
EMBO Molecular Medicine|February 23, 2026
Epigenetic dysregulation of IRF9 drives excessive interferon signaling in COPDMaria Llamazares-Prada, Uwe Schwartz, Darius F Pease, et al.
Pageof 4